...
首页> 外文期刊>BMC Pulmonary Medicine >NonTuberculous Mycobacteria infection and lung transplantation in cystic fibrosis: a worldwide survey of clinical practice
【24h】

NonTuberculous Mycobacteria infection and lung transplantation in cystic fibrosis: a worldwide survey of clinical practice

机译:Nontuberous的分枝杆菌感染和肺移植在囊性纤维化中:全球临床实践调查

获取原文
   

获取外文期刊封面封底 >>

       

摘要

In people with cystic fibrosis infection with NonTuberculous Mycobacteria is of increasing prevalence. Mycobacterium abscessus complex is of particular concern and has been associated with adverse clinical outcomes. Optimal treatment usually requires multiple antibiotics for over 12?months. When considering lung transplantation for patients with NonTuberculous Mycobacteria potential benefits must be balanced against the risks of uncontrolled infection post-transplant and significant side-effects associated with treatment. In this survey we assessed current international practice with regard to assessing and listing patients for lung transplantation. We designed a questionnaire enquiring about local practice regarding screening for NonTuberculous Mycobacteria infection, specific contra-indications to transplantation, management and segregation of patients pre- and post-transplant. The survey was sent via e-mail to 37 paediatric and adult lung transplant centres across Europe, North America and Australia. We gathered complete questionnaires from 21 centres (57% response rate). Few centres (29%) have a clear written policy regarding NonTuberculous Mycobacteria. Sixteen (76%) centres require molecular identification of NonTuberculous Mycobacteria species. Only four centres would consider infection with M. abscessus complex in itself a contra-indication for listing, however 76% regard it as a relative contra-indication. Eighty-six percent require treatment pre-transplantation. Finally, only 61% of centres had a clear policy regarding segration of patients pre-transplant and 48% post-transplant. The issue of NonTuberculous Mycobacteria infection in people with cystic fibrosis requiring lung transplantation is well-recognized however current international recommendations are not detailed and there is variation in practice between centres. There is an urgent requirement for high quality clinical data to inform decision-making.
机译:患有囊性纤维化感染的人与非萎缩的分枝杆菌的感染越来越普遍。分枝杆菌脓肿复合物特别关注并且与不良临床结果有关。最佳处理通常需要多种抗生素超过12个月。考虑到肺癌的肺移植患者潜在的效益必须抵御移植后的不受控制感染的风险和与治疗相关的显着副作用的风险。在本次调查中,我们评估了当前关于评估和上市肺移植患者的国际惯例。我们设计了关于筛选局部实践的调查问卷,探讨了不泛滥的分枝杆菌感染,对移植,治疗和移植后患者的移植,管理和分离的特异性对象。该调查通过电子邮件发送给欧洲,北美和澳大利亚的37个儿科和成人肺移植中心。我们收集了21个中心的完整问卷(57%的响应率)。很少有中心(29%)有明确的书面政策,有关不合因的分枝杆菌。十六(76%)中心需要分子鉴定不泛滥的分枝杆菌物种。只有四个中心将考虑对横坐期的脓肿复合体感染本身就是上市的反对迹象,但是76%的人认为其作为相对反应迹象。百分之八十六个百分之需要治疗预移植。最后,只有61%的中心有明确的政策,患者预移植前的患者和移植后的48%。患有肺移植的囊性纤维化囊性纤维化的人类患者的问题得到公认,但目前的国际建议未详细且中心之间存在变化。高质量的临床数据有一个迫切要求的信息来告知决策。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号